FASN and metabolic dysfunction-associated steatotic liver disease: In Hepa-RG cells exposed to NAFLD Promoting Agents, HE reduced lipid droplet accumulation (~35%) and suppressed de novo lipogenesis, with decreased expression of FASN (0.62 ± 0.06 vs. 0.39 ± 0.03 at 100 μg/mL) and SCD1 (0.05 ± 0.001 vs. 0.03 ± 0.004 at 50 μg/mL).